Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Paget's Disease Clinical Trials

A listing of Paget's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (43) clinical trials

Adavosertib External Beam Radiation Therapy and Cisplatin in Treating Patients With Cervical Vaginal or Uterine Cancer

PRIMARY OBJECTIVE: I. To determine the recommended phase II dose (RP2D) and safety profile of adavosertib (AZD1775) in combination with radiotherapy and concurrent cisplatin in patients with gynecological cancers. SECONDARY OBJECTIVES: I. To determine the acute and late toxicity of AZD1775 when administered to patients with gynecological cancer in combination ...


Abemaciclib in Treating Patients With Surgically Resectable Chemotherapy Resistant Triple Negative Breast Cancer

PRIMARY OBJECTIVES: I. To examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy. SECONDARY OBJECTIVES: I. Assess abemaciclib toxicities. II. To examine the effects of abemaciclib on the percentage of vimentin expressing invasive cancer cells. III. Within TNBC ...


Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

Overdiagnosis and overtreatment resulting from mammographic screening have been estimated to be as high as 1 in 4 patients diagnosed with breast cancer although the absence of standard definitions for measuring overdiagnosis has led to much uncertainty around this estimate. The national health care expenditure resulting from false positive mammograms ...

Phase N/A

The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment. Hypoxia-modifying therapies improve survival, but existing therapies are impractical and/or toxic. Metformin, a non-toxic drug for diabetes, has been shown to decrease tumor hypoxia in ...


Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

I. Test for the presence or absence of cytological atypia (as measured by a Masood Cytology Index Score of 14-17) in unilateral or bilateral random periareolar fine needle aspiration (RPFNA) aspirates after 12 and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm ...


Breast Cancer WEight Loss Study (BWEL Study)

This randomized controlled trial of weight loss interventions in overweight and obese women with early stage breast cancer consists of two arms, please see the arms section for more information. Patients will be randomized 1:1 within stratification factors: menopausal status (premenopausal vs. postmenopausal), hormone receptor status of the tumor (ER ...


Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

This study will include 3 dose cohorts using a 3+3 cohort dose escalation design followed by a 4th cohort (the dose expansion phase) at the maximum tolerated dose. Unless a dose limiting toxicity (DLT), defined any grade 3 or 4 toxicity, is observed requiring expansion of a cohort or a ...

Phase N/A

The PROMISE Study: Duavee in Women With DCIS

PRIMARY OBJECTIVES; To determine if CE/BZA reduces proliferation as measured by Ki-67 protein expression Secondary Objectives: To determine if CE/BZA modulates expression of ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). To determine if CE/BZA modulates a previously validated set of epithelial markers of progression. To ...


Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

PRIMARY OBJECTIVE: I. To establish the dermal tolerability and safety of Z-endoxifen hydrochloride (endoxifen) (ENX) gel administered topically to both breasts at two doses: 10 mg daily (5 mg per breast) and 20 mg daily (10 mg per breast) in comparison to vehicle placebo gel, using objective assessments based on ...


A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of multi-epitope HER2 peptide vaccine H2NVAC (H2NVAC) given every 2 weeks for 4 cycles in patients with HER2 expressing ductal carcinoma in situ (DCIS) prior to surgery. II. To determine the dose level of H2NVAC with maximum systemic and intratumoral immunogenicity ...